-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, B/uu6rWoVp1dT3G2K0Bdynh4+dTfrSOBBuuOpy79l1ro4Y1oghM+nH9MiSqDmGkB aw9kLzdLjdtbf38eqS8UvQ== 0001144204-06-033183.txt : 20060814 0001144204-06-033183.hdr.sgml : 20060814 20060814155013 ACCESSION NUMBER: 0001144204-06-033183 CONFORMED SUBMISSION TYPE: 13F-HR PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20060630 FILED AS OF DATE: 20060814 DATE AS OF CHANGE: 20060814 EFFECTIVENESS DATE: 20060814 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BAKER BROS ADVISORS LLC CENTRAL INDEX KEY: 0001263508 IRS NUMBER: 134093645 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 13F-HR SEC ACT: 1934 Act SEC FILE NUMBER: 028-10519 FILM NUMBER: 061030147 BUSINESS ADDRESS: STREET 1: 667 MADISON AVENUE STREET 2: 17TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10021 BUSINESS PHONE: 2125212418 13F-HR 1 v050155_13fhr.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 13F FORM 13F COVER PAGE Report for the Calendar Year or Quarter Ended: June 30, 2006 Check here if Amendment [ ]; Amendment Number: _____ This Amendment (Check only one.): [ ] is a restatement. [ ] adds new holdings entries. Institutional Investment Manager Filing this Report: Name: Baker Bros. Advisors, LLC -------------------------------------------- Address: 667 Madison Avenue, 17th Floor -------------------------------------------- New York, NY 10021-8029 -------------------------------------------- Form 13F File Number: 28-10519 The institutional investment manager filing this report and the person by whom it is signed hereby represent that the person signing the report is authorized to submit it, that all information contained herein is true, correct and complete, and that it is understood that all required items, statements, schedules, lists, and tables, are considered integral parts of this form. Person Signing this Report on Behalf of Reporting Manager: Name: Leo Kirby -------------------------------------------- Title: Chief Financial Officer -------------------------------------------- Phone: 212-521-2418 -------------------------------------------- Signature, Place, and Date of Signing: /s/ Leo Kirby New York, N.Y. August 14, 2006 - -------------------------- --------------------------- ---------------------- [Signature] [City, State] [Date] Report Type (Check only one.): [X] 13F HOLDINGS REPORT. (Check here if all holdings of this reporting manager are reported in this report.) [_] 13F NOTICE. (Check here if no holdings reported are in this report, and all holdings are reported by other reporting manager(s).) [_] 13F COMBINATION REPORT. (Check here if a portion of the holdings for this reporting manager are reported in this report and a portion are reported by other reporting manager(s).) List of Other Managers Reporting for this Manager: None FORM 13F SUMMARY PAGE Report Summary: Number of Other Included Managers: 0 ----------- Form 13F Information Table Entry Total: 66 ----------- Form 13F Information Table Entry Value: 764,630 ----------- (thousands) List of Other Included Managers: None
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8 TITLE OF VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY NAME OF ISSUER CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGERS SOLE SHARED NONE - ----------------- ----- ----- -------- ------- --- ---- ---------- -------- ---- ------ ---- Acadia Pharmaceuticals Inc. COM 004225108 6,749 799,643 SH SOLE 799,643 Adolor Corp. COM 00724X102 34,519 1,380,226 SH SOLE 1,380,226 Allos Therapeutics Inc. COM 019777101 16,946 4,841,848 SH SOLE 4,841,848 Altus Pharmaceuticals Inc. COM 02216N105 4,269 231,401 SH SOLE 231,401 Amylin Pharmaceuticals Inc. COM 032346108 87,879 1,780,016 SH SOLE 1,780,016 Anesiva Inc. COM 21872P501 477 62,800 SH SOLE 62,800 Anormed Inc. COM 035910108 54,117 9,411,500 SH SOLE 9,411,500 Arena Pharmaceuticals Inc. COM 040047102 3,470 299,619 SH SOLE 299,619 Array Biopharma Inc. COM 04269X105 2,319 269,696 SH SOLE 269,696 Atherogenics Inc. COM 047439104 653 50,036 SH SOLE 50,036 Autoimmune Inc. COM 052776101 32 26,100 SH SOLE 26,100 Biocryst Pharmaceuticals Inc. COM 09058V103 25,433 1,774,838 SH SOLE 1,774,838 Biomarin Pharmaceutical Inc. COM 09061G101 3,305 229,999 SH SOLE 229,999 Cerus Corp. COM 157085101 5,202 729,553 SH SOLE 729,553 Coley Pharmaceutical Group Inc. COM 19388P106 6,332 548,266 SH SOLE 548,266 Columbia Labaratories Inc. COM 197779101 3,159 902,761 SH SOLE 902,761 Corcept Therapeutics Inc. COM 218352102 406 100,200 SH SOLE 100,200 Cotherix Inc. COM 22163T103 2,689 312,300 SH SOLE 312,300 Critical Therapeutics Inc. COM 22674T105 1,305 362,649 SH SOLE 362,649 Cubist Pharmaceuticals Inc. COM 229678107 4,130 164,030 SH SOLE 164,030 Curis Inc. COM 231269101 36 26,800 SH SOLE 26,800 Cyclacel Pharmaceuticals COM 23254L108 4,821 714,286 SH SOLE 714,286 Cyclacel Pharmaceuticals Pdf. Conv. Ex. 6% PDF CONV EX 23254L207 451 95,500 SH SOLE 95,500 Cytokinetics Inc. COM 23282W100 618 98,300 SH SOLE 98,300 Genomic Health Inc. COM 37244C101 11,739 997,402 SH SOLE 997,402 GTX Inc. COM 40052B108 135 14,800 SH SOLE 14,800 Halozyme Therapeutics Inc. COM 40637H109 1,350 500,000 SH SOLE 500,000 Icagen Inc. COM 45104P104 380 76,052 SH SOLE 76,052 Idera Pharmaceuticals Inc. COM 45168K108 9,227 2,272,728 SH SOLE 2,272,728 Incyte Corp. COM 45337C102 15,245 3,314,070 SH SOLE 3,314,070 Inhibitex Inc. COM 45719T103 495 279,677 SH SOLE 279,677 Insmed Inc. COM 457669208 163 83,817 SH SOLE 83,817 Intermune Inc. COM 45884X103 10,216 621,058 SH SOLE 621,058 Isis Pharmaceuticals Inc. COM 464330109 114 18,859 SH SOLE 18,859 Ithaka Acquisition Corporation COM 465707206 346 65,000 SH SOLE 65,000 Labopharm Inc. COM 504905100 2,370 300,000 SH SOLE 300,000 Ligand Pharmaceuticals Inc. CL B 53220K207 324 38,357 SH SOLE 38,357 Medarex Inc. COM 583916101 10,060 1,046,887 SH SOLE 1,046,887 Metabasis Therapeutics Inc. COM 59101M105 16,697 2,188,354 SH SOLE 2,188,354 Monogram Biosciences Inc. COM 60975U108 200 100,789 SH SOLE 100,789 Myriad Genetics Inc. COM 62855J104 37,258 1,475,545 SH SOLE 1,475,545 Neopharm Inc. COM 640919106 4,433 831,721 SH SOLE 831,721 Neose Technologies Inc. COM 640522108 2,175 536,923 SH SOLE 536,923 Neurogen Corp. COM 64124E106 27,269 5,325,999 SH SOLE 5,325,999 Nuvelo Inc. COM 67072M301 21,896 1,315,101 SH SOLE 1,315,101 Onyx Pharmaceuticals Inc. COM 683399109 1,453 86,346 SH SOLE 86,346 Pharmacyclics Inc. COM 716933106 823 213,219 SH SOLE 213,219 Renovis Inc. COM 759885106 5,145 336,037 SH SOLE 336,037 Seattle Genetics Inc. COM 812578102 24,347 5,292,938 SH SOLE 5,292,938 Spectrum Pharmaceuticals Inc. COM 84763A108 672 172,324 SH SOLE 172,324 Sunesis Pharmaceuticals Inc. COM 867328502 6,989 1,127,214 SH SOLE 1,127,214 Tapestry Pharmaceuticals Inc. COM 876031204 6,700 2,000,000 SH SOLE 2,000,000 Telik Inc. COM 87959M109 228 13,800 SH SOLE 13,800 Theravance Inc. COM 88338T104 9,401 410,869 SH SOLE 410,869 Trimeris Inc. COM 896263100 41,391 3,602,369 SH SOLE 3,602,369 Vertex Pharmaceuticals Inc. COM 92532F100 50,440 1,374,010 SH SOLE 1,374,010 Viropharma Inc. COM 928241108 36,266 4,207,302 SH SOLE 4,207,302 Xenoport Inc. COM 98411C100 6,934 382,861 SH SOLE 382,861 Zymogenetics Inc. COM 98985T109 15,034 792,514 SH SOLE 792,514 Alexion Pharmaceuticals Notes 1.375% 2/01/2012 CONV BONDS 015351AF6 47,462 36,300,000 PRN SOLE 36,300,000 Amylin Pharmaceuticals Notes 2.5% 4/15/11 CONV BONDS 032346AD0 14,209 9,000,000 PRN SOLE 9,000,000 Biomarin Pharmaceuticals Notes 2.5% 3/29/2013 CONV BONDS 09061GAC5 20,507 18,600,000 PRN SOLE 18,600,000 Decode Genetics Notes 3.5% 4/15/2011 CONV BONDS 243586AB0 2,250 3,000,000 PRN SOLE 3,000,000 Incyte Genomics Notes 3.5% 2/15/2011 CONV BONDS 45337CAE2 14,559 19,000,000 PRN SOLE 19,000,000 Intermune Inc Notes .25% 3/01/2011 CONV BONDS 45884XAC7 5,333 6,000,000 PRN SOLE 6,000,000 Medarex Inc Notes 2.25% 5/15/2011 CONV BONDS 583916AG6 13,078 13,500,000 PRN SOLE 13,500,000
-----END PRIVACY-ENHANCED MESSAGE-----